A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite

A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 5, Iss. 3, 2015-09 ,pp. : 361-374

Karger

Access to resources Recommend Favorite

Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study

By Hara Masako   Abe Tohru   Sugawara Sachiko   Mizushima Yutaka   Hoshi Keiko   Irimajiri Shoichiro   Hashimoto Hiroshi   Yoshino Shinichi   Matsui Nobuo   Nobunaga Masashi   Nakano Shigeyuki  

Modern Rheumatology, Vol. 17, Iss. 1, 2007-02 ,pp. : 1-9

Springer Publishing Company

Access to resources Recommend Favorite

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

By  

European Neurology, Vol. 44, Iss. 4, 2000-11 ,pp. : 236-241

Karger

Access to resources Recommend Favorite

Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial

By  

Dementia and Geriatric Cognitive Disorders, Vol. 25, Iss. 5, 2008-04 ,pp. : 399-407

Karger

Access to resources Recommend Favorite